Financial Performance - The company expects a net profit attributable to shareholders of approximately CNY 11.80 million for 2025, a decrease of about CNY 27.48 million or 69.96% compared to the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be around CNY 4.79 million, down by approximately CNY 19.74 million or 80.47% year-on-year[3]. - The previous year's net profit attributable to shareholders was CNY 39.28 million, with a net profit of CNY 24.53 million after deducting non-recurring gains and losses[4]. Research and Development - The company has increased its R&D investment to enhance the competitiveness of core products and has initiated the Shanghai R&D center project[6]. - The decline in consolidated net profit is attributed to increased R&D expenses and the lack of scale in new business revenue[7]. - The company has made efforts to expand its market presence and invest in related areas of the industry chain[6]. Earnings Forecast - The data provided in the earnings forecast is preliminary and has not been audited by an accounting firm[8]. - There are no significant uncertainties affecting the accuracy of the earnings forecast as of the announcement date[8]. - Investors are advised to pay attention to investment risks as the forecast data is subject to change upon the release of the audited annual report[9]. - The earnings forecast period is from January 1, 2025, to December 31, 2025[2].

Financial Performance Expectations - The company expects a net profit attributable to shareholders to be in the range of -41,000 to -35,000 thousand yuan, compared to -15,563.65 thousand yuan in the same period last year[5]. - The net profit after deducting non-recurring gains and losses is projected to be between -38,500 and -32,500 thousand yuan, compared to -15,214.36 thousand yuan in the previous year[5]. - Basic earnings per share are expected to be between -0.5727 and -0.4889 yuan, down from -0.2174 yuan year-on-year[5]. - The company's operating revenue is anticipated to be between 31,000 and 36,000 thousand yuan, which is consistent with the previous year's revenue of 31,692.97 thousand yuan[5]. Reasons for Expected Loss - The primary reason for the expected loss is the underperformance of the film project "Fengshen Part II: The Battle of Xiqi," which faced high production and promotional costs due to a long production cycle and intense competition during the Spring Festival[7]. Asset Impairment and Financial Data - The company has conducted asset impairment assessments and made provisions for potential impairment losses based on the principle of prudence, with final amounts subject to evaluation by intermediaries and auditors[9]. - The financial data presented is preliminary and has not been audited, indicating potential uncertainties in the final report[10].

证券代码：001218 证券简称：丽臣实业 公告编号：2026-002 湖南丽臣实业股份有限公司 二、与会计师事务所沟通情况 公司与会计师事务所就本次业绩预告的事宜进行了预沟通，双方对本次业 绩预告不存在分歧。 本次业绩预告未经会计师事务所审计。 三、业绩变动原因说明 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、本期业绩预计情况 单位：万元 | 项 目 | | 本会计年度 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | 比上年 | 15,300 | ～ | 17,300 | | | | | | | | 10,911.74 | | | 同期增 | 40.22% | ～ | 58.54% | | | | 长 | | | | | | 扣除非经常性损益后的净利润 | | 14,500 | ～ | 16,500 | | | | 比上年 | | | | 10,249.86 | | | 同期增 | 41.47% | ～ | 60.98% | | | | ...

莱绅通灵珠宝股份有限公司 2025 年年度业绩预盈公告 证券代码：603900 证券简称：莱绅通灵 公告编号：2026-010 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 经财务部门初步测算，莱绅通灵珠宝股份有限公司（以下简称公司）预计 2025 年度实现归属于母公司所有者的净利润 5,800 万元左右，与上年同期（法 定披露数据）相比，将实现扭亏为盈。 经财务部门初步测算，预计公司 2025 年度实现归属于母公司所有者的扣除 非经常性损益后的净利润 6,300 万元左右。 本期业绩预告未经注册会计师审计。 二、 上年同期经营业绩和财务状况 利润总额：-1.89 亿元 归属于母公司所有者的净利润：-1.84 亿元 1 本次业绩预告适用于《上海证券交易所股票上市规则》第 5.1.1 条 "净利润实现扭亏为盈"的情形。 经财务部门初步测算，预计公司 2025 年度将出现盈利，实现归 ...

Financial Performance - The company expects a net loss attributable to shareholders of between -180 million and -160 million yuan for the year 2025, representing an increase in loss of 66.5 million to 86.5 million yuan compared to the previous year, a year-on-year increase of 71.12% to 92.51%[3] - The projected net loss attributable to shareholders after deducting non-recurring gains and losses is expected to be between -185 million and -165 million yuan, an increase in loss of 58.8 million to 78.8 million yuan compared to the previous year, a year-on-year increase of 55.33% to 74.16%[3] - The basic and diluted earnings per share for the previous year were both -0.76 yuan per share[4] Revenue and Sales - The company achieved a total sales revenue of approximately 112 million yuan in 2025, showing a certain degree of growth compared to the previous year[5] Research and Development - The company has completed the enrollment of subjects for the Phase III clinical trial of the quadrivalent influenza virus split vaccine (for children) and has submitted the production application for the trivalent influenza virus split vaccine, which is currently under review[6] - The company has increased its R&D investment significantly due to the ongoing projects, impacting the profit for the reporting period[6] Asset Management - The company has recognized an asset impairment provision and inventory write-off totaling approximately 41.99 million yuan due to risks associated with certain in-process and finished products[6] Earnings Forecast and Risks - The company has not identified any significant uncertainties that may affect the accuracy of this earnings forecast[7] - The financial data provided in the earnings forecast is preliminary and subject to final audit results[8] - The company emphasizes the importance of investor caution regarding the investment risks associated with the preliminary data[8]

证券代码：688750 证券简称：金天钛业 公告编号：2026-001 湖南湘投金天钛业科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计 2025 年年度实现净利润为 5,400 万元至 6,200 万元，与上年同期相比，预计将减少 8,971.46 万元至 9,771.46 万元，同比下降 59.13%至 64.41%。 2、预计 2025 年年度实现扣除非经常性损益的净利润为 4,300 万 元至 5,100 万元，与上年同期相比，预计将减少 8,579.79 万元至 9,379.79 万元，同比下降 62.72%至 68.57%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 （一）利润总额：17,001.18 万元。归属于母公司所有者的净利 润：15,171.46 万元。归属于母公司所有者的 ...

证券代码：688175 证券简称：高凌信息 公告编号：2026-002 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 经珠海高凌信息科技股份有限公司（以下简称"公司"）财务部门初步测算： 1、公司预计 2025 年度实现营业收入为 22,000 万元至 24,200 万元，较上年 同期减少 2,448 万元至 4,648 万元，降幅 9.19%至 17.44%。 2、公司预计 2025 年度实现归属于母公司所有者的净利润为-3,300 万元至 -4,290 万元，与上年同期相比，亏损减少 938 万元至 1,928 万元，同比减亏 17.94% 至 36.88%。 3、公司预计 2025 年度实现归属于母公司所有者扣除非经常性损益后的净利 润为-6,000 万元至-7,800 万元，与上年同期相比，亏损减少 1,217 万元至 3,017 万元，同比减亏 13.50%至 33.46%。 珠海高 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -45 million and -35 million yuan, indicating a loss compared to the previous year [3]. - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between -200 million and -150 million yuan [4]. - The earnings forecast is based on preliminary calculations by the company's finance department and has not been audited by an accounting firm [8]. - The company warns that the forecast data is preliminary and the accurate financial data will be disclosed in the official 2025 annual report [9]. Previous Year Performance - In the previous year, the total profit was 13.6082 million yuan, with a net profit attributable to shareholders of the parent company of 12.5637 million yuan [6]. - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, was -22.5586 million yuan in the previous year [6]. Market Conditions - The decline in performance is primarily due to a sluggish market for the company's main product, float glass, leading to a decrease in sales prices and gross margin [7].

证券代码：603363 证券简称：傲农生物 公告编号：2026-006 福建傲农生物科技集团股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 业绩预告的具体适用情形：实现盈利，且净利润与上年同期相比下降 50% 以上。 福建傲农生物科技集团股份有限公司（以下简称"公司"）预计 2025 年年 度实现归属于上市公司股东的净利润为 9,000 万元到 13,500 万元，与上年同期相 比，将减少 44,434.50 万元到 48,934.50 万元，同比减少 76.70%到 84.47%。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计 2025 年年度实现归属于上市公司股东的净利 润为 9,000 万元到 13,500 万元，与上年同期相比，将减少 44,434.50 万元到 48,934.50 万元，同比减少 76.70%到 84.47% 2、经财务部门初步测算， ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2025 to be between -82.4 million and -123.6 million yuan[2] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 2.4 million and 3.6 million yuan[2] - The previous year's net profit attributable to shareholders was -11.535 million yuan, with a net profit of -26.0309 million yuan after deducting non-recurring gains and losses[4] Reasons for Expected Loss - The expected loss for 2025 is primarily due to bad debt provisions related to litigation caused by the controlling shareholder's illegal borrowing[6] Caution for Investors - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by registered accountants[7] - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change upon the release of the audited annual report[8]